You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
申聯生物(688098.SH):2024年淨虧損4553.59萬元
格隆匯 02-27 17:04

格隆匯2月27日丨申聯生物(688098.SH)公佈2024年度業績快報報告期內,公司實現營業收入30,341.47萬元,較上年增加0.64%;歸屬於母公司所有者的淨利潤-4,553.59萬元,較上年減少244.47%。2024年度,公司蓄力拓展產品銷售,多措並舉提升產品市場競爭力,營銷持續優化佈局尋求業績增長,產品進入大型養殖集團供應鏈體系逐步增加,牛羊口蹄疫滅活疫苗、豬圓環疫苗等新產品銷售佔比也明顯提升,產品銷量持續上升。但受動保行業競爭加劇,疫苗產品價格下降等不利影響,在產品銷售量有所上升的情況下,公司營業收入保持穩定,但毛利率下降。在此情況下,公司持續並行推進短期、中長期戰略發展規劃,以先進的生物醫藥技術爲支撐,以滿足重大動物疫病臨牀需求爲出發點,持續開發有競爭優勢的新項目和新產品。其中,環狀mRNA疫苗產品研發進展順利,公司病毒樣顆粒(VLP)疫苗等先進技術及產品出海具備了充分的條件,基因工程亞單位疫苗等新疫苗項目研發取得進展,2024年度公司研發投入有所上升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account